Zhu Peng-Chong, Tong Qiang, Zhuang Zhuang, Wang Zi-Hao, Deng Li-Hui, Zheng Guo-Qing, Wang Yan
Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Front Physiol. 2019 Oct 16;10:1292. doi: 10.3389/fphys.2019.01292. eCollection 2019.
Ginkgolide B (GB) is an extract of dried Ginkgo biloba leaves and possesses various pharmacological activities in the cardiovascular system. Herein, we aim to assess the available preclinical evidence and possible mechanisms of GB for myocardial ischemia/reperfusion injury. The study quality score was assessed using the CAMARADES 10-item checklist. Rev-Man 5.3 software was used for data analyses. Nineteen studies with total 437 animals were included for analysis. Meta-analyses indicated that GB interventions significantly reduce myocardial infarct size and cardiac markers when compared with control ( < ). The possible mechanisms via which GB exerts cardioprotective effects are mainly associated with anti-oxidation, anti-inflammation, anti-apoptosis, and improvement of energy metabolism. Our study indicates that GB might be a promising cardioprotective agent for myocardial ischemia/reperfusion injury and may contribute to future clinical trial design.
银杏内酯B（GB）是银杏叶干燥提取物，在心血管系统中具有多种药理活性。在此，我们旨在评估GB对心肌缺血/再灌注损伤的现有临床前证据及可能机制。使用CAMARADES 10项清单评估研究质量得分。采用Rev-Man 5.3软件进行数据分析。纳入19项研究，共437只动物进行分析。荟萃分析表明，与对照组相比，GB干预可显著减小心肌梗死面积并降低心脏标志物水平（<）。GB发挥心脏保护作用的可能机制主要与抗氧化、抗炎、抗凋亡及能量代谢改善有关。我们的研究表明，GB可能是一种有前景的用于心肌缺血/再灌注损伤的心脏保护剂，可能有助于未来的临床试验设计。
Zotero 插件
